 |
| Main Menu | News By Date | News By Supplier | News By Category | About Us |
|
BTG REPORTS POSITIVE RESULTS FROM UK VARISOLVE TRIALS
The trials were conducted in two medical centres, South Manchester University and Aberdeen Royal Infirmary. Forty-one patients with moderate to severe varicose veins, who would normally be treateded with surgery, participated in the trials. Patients each received either one or two injection treatments within a one-week interval. All patients were able to return to work the same or following day. The treatment was well tolerated and no significant side effects were detected. The overall success rate of the treatment was 81% and was comparable to the outcome from surgical treatment. Success was measured by ultra-sound examination showing elimination of abnormal retrograde blood flow into the veins and of closure of the varicose vein. Varisolve is an outpatient treatment for varicose veins and is being developed by Provensis to provide an alternative to surgery. Over 150 million people in the US and Europe suffer from significant varicose veins. Four million new cases of varicose veins develop each year. Professor Charles McCollum who led the work in Manchester said: "I am very excited by the Varisolve treatment and believe that with the right personnel, equipment and training, people suffering from major varicose veins can be treated as outpatients with remarkably little discomfort. The results are at least as good as surgery without the scars or the painful recovery time." Ian Harvey, Chief Executive Officer of BTG and Chairman of Provensis, commented: "We are very pleased with these results from this independent study. They have reconfirmed our expectations for Varisolve and have demonstrated the potential of the procedure as an outpatient alternative to surgery for the treatment of varicose veins."
|
| ©2008 New Materials International |